Provided by Tiger Trade Technology Pte. Ltd.

AC Immune SA

2.81
+0.19007.25%
Post-market: 2.810.00000.00%16:10 EDT
Volume:352.70K
Turnover:965.11K
Market Cap:285.98M
PE:-5.34
High:2.84
Open:2.64
Low:2.57
Close:2.62
52wk High:4.00
52wk Low:2.10
Shares:101.77M
Float Shares:39.19M
Volume Ratio:1.58
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5264
EPS(LYR):-0.8828
ROE:-78.53%
ROA:-16.04%
PB:6.76
PE(LYR):-3.18

Loading ...

AC Immune Price Target Maintained with a $8.00/Share by BTIG

Dow Jones
·
Sep 24

AC Immune Rises After Parkinson's Drug Shows Promise in Mid-Stage Trial

Reuters
·
Sep 23

AC Immune Reports Positive Week-100 Safety, Immunogenicity in Phase 2 VacSYn Trial of Parkinson’s Vaccine ACI-7104

Reuters
·
Sep 23

AC Immune Reports Positive Safety & Immunogenicity at Week-100 in Part 1 of Vacsyn Phase 2 Trial of ACI-7104

THOMSON REUTERS
·
Sep 23

AC Immune Ag - All Primary Endpoints Met in Part 1 of Vacsyn Phase 2 Trial for ACI-7104

THOMSON REUTERS
·
Sep 23

AC Immune Ag - Discussions with FDA Regarding ACI-7104 Development Path Planned for Early 2027

THOMSON REUTERS
·
Sep 23

AC H1 Net Profit at 10.1 Mln Zlotys

Reuters
·
Aug 26

Promising Penny Stocks To Consider In August 2026

Simply Wall St.
·
Aug 22

AC Immune Price Target Maintained with a $8.00/Share by BTIG

Dow Jones
·
Aug 20

AC Immune Reports Positive Interim Phase 1 Data for NLRP3 Inhibitor ACI-19764

Reuters
·
Aug 20

AC Immune Announces Positive Preliminary Phase 1 Data for Nlrp3 Inhibitor ACI-19764

THOMSON REUTERS
·
Aug 20

AC Immune - Full Phase 1/1B Results for ACI-19764 Expected in H1 2027

THOMSON REUTERS
·
Aug 20

AC Immune - ACI-19764 Safe and Well Tolerated with Confirmed Csf Penetration in Phase 1

THOMSON REUTERS
·
Aug 20

AC Immune - Based on Pk Data Therapeutic Dose is Expected to be ≤10Mg Once Daily

THOMSON REUTERS
·
Aug 20

AC Immune - no Serious Adverse Events or Treatment Withdrawals Reported for ACI-19764

THOMSON REUTERS
·
Aug 20

U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,

Reuters
·
Aug 11

U.S. Stocks on the MOVE-Duke Energy, Sea, Cardinal Health

Reuters
·
Aug 11

AC Immune - Full Week-100 Results from Part 1 VacSYn Trial Expected in H2 2026

Reuters
·
Aug 11

AC Immune receives fast track designation, clearance for ACI-7104 IND

TIPRANKS
·
Aug 11

AC Immune Jumps After US FDA Grants Fast-Track Status for Parkinson's Disease Drug

Reuters
·
Aug 11